At Pathway Health, we are committed to delivering personalized care to help improve a patients’ quality of life. We strive to provide patients with timely access to personalized treatment plans using advanced and clinically-proven solutions to achieve the best outcomes.

1. w w w . p a t h w a y h e a l t h . c a
Corporate Presentation
Pathway
Health
September 2021

2. Certain statements contained in this presentation constitute forward-looking statements. The words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions typically are used to
identify forward-looking statements. By their nature, forward-looking statements and information involve known and
unknown opportunities, costs, risks and uncertainties that may cause actual results to differ materially from those
anticipated. Except for statements of historical fact, certain information contained herein constitutes forward-looking
statements which include management’s assessment of future plans and operations and are based on current internal
expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect.
The use of forward-looking statements reflects our current views, expectations, estimates and/or projections with respect
to our performance, business and future events, and in this presentation includes statements relating to, among others:
expectations regarding our business; expectations relating to our business goals, objectives and schedules; expectations
regarding the cannabinoid based therapy industry, including Canada’s position therein; expectations regarding the
acceptance of cannabinoid based therapies in the medical community; expectations regarding our clinical development
plans; expectations regarding development of new intellectual property, including from cannabinoid product combinations;
expectations related to the anticipated closing of the subscription receipt offering and reverse take-over with a Capital Pool
Company; the terms and conditions of the subscription receipt offering; and the use of proceeds from the subscription
receipt offering. Forward-looking statements are prepared by management and based on the then-current expectations,
forecasts and assumptions about the business and the industry and markets in which we operate, including, among others:
that there will be no unforeseen delays, disruptions, market forces, regulations or laws that will prevent us from operating
our business; that we will be able to obtain the capital we require; that the subscription receipt offering has closed; that the
escrow release conditions in respect of the subscription receipt offering have been fulfilled; and that the reverse take-over
has been completed. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties
and assumptions which are difficult to predict, including, without limitation: that we may experience unforeseen delays,
financing difficulties or costs that will impact our projects, operations, financial performance or liquidity; that we will not be
able to advance our business plan or continue operations; that we will not be able to obtain insurance for our operations;
that we will not be able to protect our intellectual property; that we will not be able to develop and commercialize, or
obtain regulatory approvals to commercialize, products derived from our intellectual property; that we will not be able to
recruit physicians for our clinics; that regulatory approvals of products developed from our intellectual property may result
in significant delays; that development of cannabinoid based therapies may expose us to liability claims in excess of our
insurance coverage; and those risks relating to the occurrence of national disasters, hostilities, acts of war or terrorism, our
reputation, our key personnel, competition, employee relations, changes in the cannabinoid based therapy market
generally, potential downturns in economic conditions, pandemics, foreign exchange fluctuations, fluctuations in the
currency markets, inflationary pressures, changes in interest rates, changes in regulatory requirements which may alter or
prohibit investment in our business, or changes in national and local government legislation, taxation, controls, regulations
and political or economic developments in Canada or any other country in which we operate or intend to operate.
These risks, as well as others, could cause actual results and events to differ materially from those anticipated in such
forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements and
information, which are qualified in their entirety by this cautionary statement. These statements speak only as of the date
of this presentation and we do not undertake any obligations to update such forward-looking statements, except as
required by applicable securities law.
To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or
“financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to
demonstrate the potential benefits of the company’s business plans and strategies, and the reader is cautioned that this
information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-
oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with
forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out
herein. The company’s results of operations and estimated and forecasted revenue may differ materially from
management’s current expectations. Such information is presented for illustrative purposes only and may not be an
indication of the company’s actual future results of operations or earnings.
Market and industry data contained in this presentation is based upon information, surveys or studies conducted by
independent third parties and independent industry or general publications and management’s knowledge of, and
experience in, the markets in which we operate or intend to operate. We have no reason to believe that such third-party
information is false or misleading in any material respect, however market and industry data is subject to variation and
cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature
of the data gathering process and other limitations and uncertainties inherent in any statistical survey. This third-party
information has not been independently verified by us or any of our respective directors, officers or representatives and no
representation is given as to the accuracy of any of the data from third party sources referred to in this presentation.
The securities being offered pursuant to the subscription receipt offering are being offered on a private placement basis in
reliance upon prospectus and registration exemptions under applicable securities legislation. Resale of the securities offered
hereunder will be subject to restrictions under applicable securities legislation, which will vary depending on the relevant
jurisdiction. Generally, such securities may be resold only pursuant to an exemption from the prospectus and registration
requirements of applicable securities legislation or pursuant to an exemption order granted by appropriate securities
regulatory authorities.
The securities being offered pursuant to the subscription receipt offering have not, nor will they be, registered under the
United States Securities Act of 1933, as amended, or the securities laws of any state of the United States and may not be
offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S.
registration or an applicable exemption from the U.S. registration requirements. This presentation does not constitutes an
offer for sale of securities in the United States.
Forward Looking Statement
DISCLAIMER

3. 3
Investment Highlights
Largest medical cannabis service provider in Canada
Leading partner with Canadian pharmacy
companies for medical cannabis consultations,
pharmacist education
• Agreements signed covering ~2,000 retail
pharmacy locations nationally
• Cannabis Health Product market >$2 billion
• Proprietary, national distribution network
One of the largest providers of chronic pain services
in Canada
3-year revenue growth - $600k (2018) to $12.6
million (2020) 1
Investment
1. These are unaudited revenue figures. The revenue figures include management's best
estimate of additional revenue in relation to the acquisition of NHS, NACM Clinic and Pharmacy
business and NMI as if it happened January 1, 2020.

4. 4
The Opportunity
Partnering
Opportunities
Workers Comp, unions, insurance
companies, family medical practices,
allied health, mental health, LPs, First
Nations, government, clinical trials
Fragmented
chronic pain industry
Opportunity to roll up industry -
accretive acquisitions to build on
existing infrastructure
Pharmacy
Partnerships
Patient assessments for pain
management/medical cannabis;
Cannabis Health Product (CHP)
development and distribution
Cannabis 3.0
Focus on medical - including CHPs;
Building product co-brands with
pharmacy partners – proprietary
distribution network for a new, multi
billion-dollar product category

5. 5
Cannabis 3.0 and Canadian Pharmacies
“The Cannabis Health Products (CHP) category is expected to grow
exponentially in the coming years.”
Cannabis 3.0 - bringing the benefits of cannabis derivatives (e.g. CBD) into
mainstream health products
 NPA’s 1 pitch to the CDN government – “(P)harmacists have an important
role in providing clinical information to patients at the point of sale.”
January 2021
Pharmacies have limited or no experience with the category - New
consumer packaged goods category
 PHC is a credible partner for pharmacies – medical/scientific foundation,
expertise in medical cannabis, strong ecosystem for product development
1. NPA – Neighbourhood Pharmacy Association

6. What has been the
pharmacy industry’s
position on cannabis & CHPs?
6
As medication experts, pharmacists are best equipped to provide clinical advice to
patients & appropriate oversight in the safe management and dispensing of medical
cannabis.
Pharmacist management and dispensing of medical cannabis is the best option to
strengthen any future framework and protect patient and public safety.”
Canadian Pharmacists Association
Canadian Pharmacists
Association
Canadian Pharmacists Association
April 2016

7. 7
Ontario College of Pharmacists
“As medication therapy experts, pharmacists are in a unique position
to provide quality and effective patient care for those who consume
cannabis. This may take place through educating patients about the
consumption of cannabis … and through collaboration with other
health care professionals to enhance patient safety.
(T)he Ontario College of Pharmacists would not oppose any federal or
provincial legislation that would permit the dispensing of non-
smoked forms of cannabis for medical use within pharmacies...”
August 2016

8. 8
Evolution of Pharmacy & Cannabis (04/17 – 05/19)
Intro of Bill C-45
04/17
OCP Task Force releases
Cannabis Position Paper
05/18
Pathway signs deal with
Lovell Drugs
03/19
OCP endorses Cannabis
Position Paper
06/18
Cannabis legalized in
Canada
10/18
OCP requires
pharmacists to
complete cannabis
education
05/19
OCP establishes task
force on cannabis
09/17
Shoppers begins
cannabis sales online
01/19
Federal Government Pharmacy Pathway Health
OCP - Ontario College of Pharmacists

9. 9
Evolution of Pharmacy & Cannabis (05/19 - present)
Public consultation
on potential market
for CHPs
05/19
Cannabis
2.0 released
10/19
Pathway signs deal
with Sobeys
07/21
First brick & mortar
cannabis pharmacy
opens in Ottawa
06/20
NPA Medical Cannabis
Position Statement
released
01/21
Cannabis 3.0 released
?
Pathway’s Cannabis &
Patient Care for
Pharmacists course
given accreditation
08/19
Pathway signs deal with
PharmaChoice
06/21
Federal Government Pharmacy Pathway Health
CHPs – Cannabis Health Products | NPA - Neighbourhood Pharmacy Association
Pathway Health has been working alongside the pharmacy industry for 3
years preparing for Cannabis 3.0

10. 10
Pharmacy/Pathway Economics
Two types of existing agreements with
pharmacy partners– medical cannabis
consultations; and education
 Third type pending – products (CHPs)
Medical cannabis consultations
 Assumptions:
 Average 2 new patients per month per
on-boarded pharmacy – each year
 Potential average annual gross revenue
to PHC per patient > $500 1 2
 >$10 million annual revenue
opportunity – cumulative growth
Agreements in place with 3 national pharmacy chains covering ~ 2,000 Canadian Pharmacies
OCP - Ontario College of Pharmacists

11. 11
Products – Bringing Medical Cannabis to Pharmacies
1. https://chfa.ca/en/regulatory/CBD-Economic-Report
2. https://mjbizdaily.com/chart-week-profit-margins-infused-products-can-sky-high/
3. Canadian Pharmacists Association, https://www.pharmacists.ca/pharmacy-in-canada/pharmacists-in-canada/
In discussions with pharmacy partners regarding
development, branding and distribution of CHPs
through retail pharmacy locations across Canada
 Products include fast-acting CBD capsules,
extended-release tablets, deep penetrating
gels, etc.
Forecast legal changes to CBD market
worth $2.45 billion by 2023 1
Profit margins can be significantly higher than the
average for other consumer goods such as
alcohol, beer, wine, soft drinks and cigarettes 2
Canada has approximately 42,500 licensed
pharmacists working in more than 10,000
pharmacies 3

12. 12
Chronic Pain – A Large and Growing Problem
1 Schopflocher et al., 2011; Reitsma et al., 2011; Steingrimsdottir et al., 2017, Canadian Pain Task Force Report, June 2019
2 https://www.benefitscanada.com/benefits/health-benefits/chronic-pain-costs-employers-52439
3 http://www.canada.com/health/live+this+life+pain+Canadians+with+chronic+pain+struggling+find+help+hope/5485154/story.html
>$50 billion in health care resources and
productivity losses 2
Burdensome
1-3 Years average wait time for
treatment at publicly-funded pain clinics
in Canada 3
Under capacity
1 in 5 Canadian adults experience
chronic pain 1
Prevalent
Specialized pain services are largely
inaccessible
Lack of specialists

13. 13
Clinic Growth Plans
Current 9 locations include Toronto, Montreal (3),
Chateauguay, Magog, Saskatoon, Winnipeg, Selkirk
 Goal of 12 – 15 clinics across Canada –
covering catchment areas of pharmacy
locations
 Targeting established clinics targeted for BC,
AB and East Coast through acquisition or
affiliation
Expansion of interventional pain model into current
locations – e.g adding new products and services

14. 14
Growth Drivers
Sign additional pharmacy agreements for new
patient consultations, education
New pharmacy agreements on CHPs – development,
distribution and co-branding
Regional market expansion of clinics in Canada
 Continue rollup of patients and select clinics
 Expand new clinical services to existing clinics
Medical Sales License for B2B and B2C sales
Growth Drivers

15. 15
Financial Overview
1. Gross margins on Provincial Billings expected to increase as further integration of recent acquisitions occurs.
2. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition of NHS, NACM Clinic and Pharmacy business
and NMI as if it happened January 1, 2020.
 Education and marketing revenue
 100% gross margins
LP Revenue
$3.9
 Physician billings
 20% gross margins1
Provincial Billing
$5.9
 Patient private pay
 80% gross margins
Non-Insured Billing
$0.5
$0.6
$6.6
$12.6
$0.0
$2.0
$4.0
$6.0
$8.0
$10.0
$12.0
$14.0
1
 Quebec orthopaedic sales
 70% gross margins
Product Sales
$2.2
Revenue (C$MM)2
31.4%
46.8%
17.8%
4%
2020E Revenue Contribution
2018 2020E
2019
Provincial Billing
LP Revenue
Product Sales
Non-Insured Billing

16. -
2.0
4.0
6.0
8.0
10.0
12.0
TEV/REV CAP/REV
Mean Median PHC.V
16
Industry Comparable 1 2
1. High and low removed. Stock prices dated July 21, 2021
2. Based on reported 2020 financials
Industry Comparable
Akumin Inc.
Carebook Technologies Inc..
CloudMD Software and Services Inc.
Empower Clinics
Greenbrook TMS Inc.
Jack Nathan Health
MCI OneHealth
Medical Facilities Corp.
MindBeacon Holdings Inc.
Neupath Health Inc.
Skylight Health
ThinkResearch (TRC Holdings)
VitalHub Corp
WELL Health Technologies

17. 113,497,218 fully diluted shares outstanding. No derivative securities have an exercise price less than issue price of $0.50 per share 17
Cap Structure
Percentage Shares
Investor Group Ownership Outstanding
Cura-Can Health Corp. 55.5% 51,638,711
Converted notes 11.6% 10,864,108
CPC (Colson Capital) 3.1% 2,856,171
Canaccord sub receipts 29.6% 27,600,000
Shares to Agents 0.2% 150,000
GRAND TOTAL 100% 93,108,990

18. Summary
18
Leading partner with Canadian Pharmacies on Medical Cannabis
1. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition of
NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.
 Signed 6 agreements with some of the nation’s largest retail pharmacies > becoming the leading partner for pain
products and services for thousands of Canadian pharmacies
 In discussion with several national pharmacy companies on CHP development, branding and distribution in
preparation for Cannabis 3.0
Largest out-of-hospital chronic pain clinic in Canada
 Becoming the dominant out-of-hospital pain management business in Canada
 6 acquisitions since January 2019
 Revenue has grown from $600K to almost $13 million in 3 years. 1
 Developing a unique IT platform allowing the company to scale pharmacy initiative and expand its telemedicine
services
Proven management
 Expertise and experience in healthcare, cannabis, M&A, capital markets

19. Wayne Cockburn
President
(905) 505-0770
wayne.cockburn@pathwayhealth.ca
Dave Burwell
Vice President, The Howard Group
(403) 410-7907
dave@howardgroupinc.com
Investor Relations
Contact
Information

20. 20
Appendices

21. 21
Ken Yoon
CEO
25 years of experience in consulting,
financing, investing and building innovative
private and public companies with over
$500M in transactions. Prior to PHC, Mr.
Yoon was CFO at a TSX listed pharmaceutical
company and a private nanotech company,
an investment professional at what was one
of largest venture capital firms in Canada,
and held several positions at Ernst & Young,
notably as a co-founder of a multi-
disciplinary business advisory group. Mr.
Yoon is a CPA, CA, holds an MBA, Law
Degree, and BSc.
Leadership Team
Wayne Cockburn
President
Over 25 years of healthcare experience,
including 20 years at the C-level, specializing
in strategic planning, corporate finance and
capital market strategies, corporate
partnering, corporate governance and
mergers and acquisitions. Mr. Cockburn
brings over 35 years of capital market
experience and has served on the board of
directors of U.S. and Canadian private and
public companies for more than 20 years.
Kim Wei
Chief Commercial Officer
Over 30 years of executive level leadership
experience in healthcare. Mr. Wei has a track
record for developing and delivering
innovative allopathic and complementary
medicine models in North America.
Mr. Wei is a co-founder of The Clinic
Network and has helped grow PHC to be a
Canadian delivery system with corporate
and joint-venture clinics, in multiple
healthcare disciplines. Mr. Wei has acted as
a Director on multiple Canadian and
international company Boards.

22. 22
Leadership Team
Aura Balboa
CFO
Over 15 years of finance and operations
experience to PHC. Ms. Balboa began her
career in public accounting with Deloitte.
She then held a number of finance roles
with increasing responsibilities at multiple
pharmaceutical companies both in Canada
and the US. Her most recent role was
Director of Finance at Acerus
Pharmaceuticals Corporation, a Canadian
pharmaceutical company listed on the TSX.
Pram Sandhu
VP, Pharmacy Programs & Regulatory Affairs
Over 20 years of experience in various facets
of the healthcare sector. Mr. Sandhu is the
former VP of Medical Operations and
Business Optimization for National Access
Cannabis Medical. Mr. Sandhu is also an
active clinical pharmacist, who has a passion
for developing innovative programs in
regulated environments. In 2014, he was a
recipient of the Trillium Health Partners
Allied Health Professional Award. Mr.
Sandhu holds a Professional Certificate in
Cannabis Science and Medicine from the
University of Vermont’s Larner College of
Medicine.

23. Board of Directors 1
23
Michael Steele
Chairman
Mr. Steele is an engineer and financier with
over 30 years of experience in structured
investments and new business start-ups. Mr.
Steele has provided consulting services to
various industry sectors including real
estate, mining, oil and gas, and the Canadian
medical cannabis sector. Since 2013 Mr.
Steele has consulted to or provided
financing to various companies in the
Canadian medical cannabis industry. Mr.
Steele graduated from the University of
Waterloo with a P.Eng (BASc) in civil
engineering and received his MBA in 1981.
Alison Wright
Independent Director
Ms. Wright has over 20 years of
management experience in the construction
and property management industries.
Currently, Ms. Wright is the President of
Alwright Investments Inc., a Canadian
property management and investment
company she founded in 2012. Ms. Wright
has served as a director on several boards of
private companies in both Canada and the
United States. Ms. Wright graduated from
the University of Toronto in 1991 and holds a
Bachelor of Science.
Kenneth Howling
Independent Director
Mr. Howling has over 25 years of healthcare
industry experience in senior financial
positions; including 11 years with Bausch
Health (formerly Biovail Corporation), as CFO &
Senior VP, Finance & Corporate Affairs; five
years as CFO of Acerus Pharmaceuticals
Corporation; & five years as CFO with Pharma
Patch PLC. During his career, Mr. Howling has
contributed to the success of multiple start-up
companies & has taken multiple companies
through the IPO process. Mr. Howling is a
graduate of the ICD/Rotman Director Program
& formerly a Certified Public Accountant
(inactive license).
1. Includes Ken Yoon

24. 01
02
03
04
05
06
01 02
03
05
04
06
24
Pharmacy customer receives preliminary assessment from Pharmacist.
Pharmacist sends customer to Pathway for medical consultation
If appropriate, Pathway prepares script and sends it, along with medical
records, to relevant Licensed Seller (LS)
Customer pays LS for product and product is shipped directly to customer
LS pays Pathway an education fee (%)
Pathway provides product information to Pharmacist for updating their
records
Pharmacies - Facilitating Access To Cannabis Sales
Pharmacy Customer Pathway
Licensed Seller